- Home
- VMD vs DMAC Comparison
VMD vs DMAC Comparison
Compare VMD & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- DMAC
- Stock Information
- Founded
- VMD 2006
- DMAC 2000
- Country
- VMD United States
- DMAC United States
- Employees
- VMD N/A
- DMAC N/A
- Industry
- VMD
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- DMAC Health Care
- Exchange
- VMD Nasdaq
- DMAC Nasdaq
- Market Cap
- VMD 288.1M
- DMAC 267.7M
- IPO Year
- VMD N/A
- DMAC N/A
- Fundamental
- Price
- VMD $7.57
- DMAC $5.77
- Analyst Decision
- VMD
- DMAC Strong Buy
- Analyst Count
- VMD 0
- DMAC 3
- Target Price
- VMD N/A
- DMAC $7.00
- AVG Volume (30 Days)
- VMD 104.0K
- DMAC 90.6K
- Earning Date
- VMD 03-10-2025
- DMAC 05-07-2025
- Dividend Yield
- VMD N/A
- DMAC N/A
- EPS Growth
- VMD 12.00
- DMAC N/A
- EPS
- VMD 0.28
- DMAC N/A
- Revenue
- VMD $224,257,000.00
- DMAC N/A
- Revenue This Year
- VMD $23.46
- DMAC N/A
- Revenue Next Year
- VMD $12.43
- DMAC N/A
- P/E Ratio
- VMD $27.54
- DMAC N/A
- Revenue Growth
- VMD 22.54
- DMAC N/A
- 52 Week Low
- VMD $6.21
- DMAC $2.14
- 52 Week High
- VMD $9.85
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- VMD 42.70
- DMAC 45.29
- Support Level
- VMD $7.33
- DMAC $5.29
- Resistance Level
- VMD $7.97
- DMAC $5.90
- Average True Range (ATR)
- VMD 0.24
- DMAC 0.29
- MACD
- VMD 0.01
- DMAC -0.08
- Stochastic Oscillator
- VMD 37.98
- DMAC 38.04
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.